Photo of Patrick Y. Wen,  MD

Patrick Y. Wen, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 632-2166
Fax: (617) 632-4773


pwen@partners.org

Patrick Y. Wen, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Neurology, Harvard Medical School
  • Director, Center For Neuro-Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research is directed towards the deveiopment of new therapies for brain tumors and leptomeningeal metastases using gene therapy, inhibitors of angiogenesis, hormonal therapy and radionuclides. I am also interested in the neurologic complications in cancer patients.

Publications

Powered by Harvard Catalyst
  • Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. 2015; 17:1051-63. PubMed
  • Rahman R, Catalano PJ, Reardon DA, Norden AD, Wen PY, Lee EQ, Nayak L, Beroukhim R, Dunn IF, Golby AJ, Johnson MD, Chiocca EA, Claus EB, Alexander BM, Arvold ND. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J. Neurooncol. 2015; 124:137-46. PubMed
  • Wen PY. Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases. 2015; 17:915. PubMed
  • Aizer AA, Du R, Wen PY, Arvold ND. Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. J. Neurooncol. 2015. PubMed
  • Reardon DA, Ligon KL, Chiocca EA, Wen PY. One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med 2015; 19:471-7. PubMed
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY, . Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015; 16:e270-e278. PubMed
  • Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Transl Oncol 2015; 8:137-46. PubMed
  • Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. 2015. PubMed
  • Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. 2015. PubMed
  • Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, Sullivan RJ, Cherniack AD, Garraway LA, Stemmer-Rachamimov A, Reardon DA, Wen PY, Brastianos PK, Curry WT, Barker FG, Hahn WC, Nahed BV, Ligon KL, Louis DN, Cahill DP, Meyerson M. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol 2015. PubMed
  • Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res 2015. PubMed
  • Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. 2015; 17:488-504. PubMed
  • Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM. Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. Int J Radiat Oncol Biol Phys 2015. PubMed
  • Neagu MR, Huang RY, Reardon DA, Wen PY. How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol 2015; 17:343. PubMed
  • Rinne ML, Wen PY. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Oncology (Huntingt) 2015; 29:265, 275. PubMed
  • Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. 2015. PubMed
  • Reardon DA, Wen PY. Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol 2015; 12:69-70. PubMed
  • Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 2015; 84:280-6. PubMed
  • Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. 2015. PubMed
  • Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. 2015. PubMed
  • Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015; 122:4-23. PubMed
  • Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol 2015; 6:33. PubMed
  • Jordan JT, Wen PY. Novel chemotherapeutic approaches in adult high-grade gliomas. Cancer Treat Res 2014; 163:117-42. PubMed
  • Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J. Neurooncol. 2014. PubMed
  • Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J. Neurooncol. 2014. PubMed
  • Gilbert MR, Armstrong TS, Pope WB, van den Bent MJ, Wen PY. Facing the future of brain tumor clinical research. Clin Cancer Res 2014; 20:5591-600. PubMed
  • Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. 2014; 16:1541-6. PubMed
  • Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. 2014; 16:1441-1458. PubMed
  • Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. 2014; 16:1523-9. PubMed
  • Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2014; 12:1517-23. PubMed
  • Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J. Neurooncol. 2014. PubMed
  • Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. 2014; 16:vii2-vii11. PubMed
  • Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. 2014; 16 Suppl 8:viii7-13. PubMed
  • Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). 2014; 16:vii36-vii47. PubMed
  • Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA. Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies. Cancer 2014. PubMed
  • Barone A, Sengupta R, Warrington NM, Smith E, Wen PY, Brekken RA, Romagnoli B, Douglas G, Chevalier E, Bauer MP, Dembowsky K, Piwnica-Worms D, Rubin JB. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. 2014. PubMed
  • Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. 2014. PubMed
  • Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. 2014. PubMed
  • Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. 2014. PubMed
  • Lee EQ, Ruland S, LeBoeuf NR, Wen PY, Santagata S. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. J Clin Oncol 2014. PubMed
  • Wen PY. Point/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma? 2014; 16:1032. PubMed
  • Aizer AA, Arvold ND, Catalano P, Claus EB, Golby AJ, Johnson MD, Al-Mefty O, Wen PY, Reardon DA, Lee EQ, Nayak L, Rinne ML, Beroukhim R, Weiss SE, Ramkissoon SH, Abedalthagafi M, Santagata S, Dunn IF, Alexander BM. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. 2014. PubMed
  • Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. 2014. PubMed
  • Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J. Neurooncol. 2014. PubMed
  • Akgoz A, Rahman R, You H, Qu J, Hamdan A, T Seethamraju R, Wen PY, Young GS. Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma. J. Neurooncol. 2014. PubMed
  • Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN. The role of cytotoxic chemotherapy in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2014. PubMed
  • Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC. The role of targeted therapies in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2014. PubMed
  • Wen PY, Junck L. Bevacizumab for glioblastoma: What can we learn from patterns of progression? Neurology 2014. PubMed
  • Reardon DA, Wen PY. Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol 2014. PubMed
  • Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. 2014; 16:567-78. PubMed
  • Lee JW, Norden AD, Ligon KL, Golby AJ, Beroukhim R, Quackenbush J, Wells W, Oelschlager K, Maetzold D, Wen PY. Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study. Epilepsy Res 2014. PubMed
  • Wen PY. Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas? 2014; 16:329. PubMed
  • Arrillaga-Romany I, Reardon DA, Wen PY. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs 2014; 23:199-210. PubMed
  • Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. 2014; 16:173-8. PubMed
  • Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist 2014; 19:75-81. PubMed
  • Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 2013; 110:19059-64. PubMed
  • Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J. Neurooncol. 2013; 115:267-76. PubMed
  • Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer 2013; 119:3479-88. PubMed
  • Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J. Neurooncol. 2013; 115:71-7. PubMed
  • Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M, . Central nervous system cancers. J Natl Compr Canc Netw 2013; 11:1114-51. PubMed
  • Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY, . Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 2013; 14:e407-16. PubMed
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY, . Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 2013; 14:e396-406. PubMed
  • Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 2013; 19:1178-83. PubMed
  • Chinnaiyan P, Won M, Wen PY, Rojiani AM, Wendland M, Dipetrillo TA, Corn BW, Mehta MP. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2013; 86:880-4. PubMed
  • Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. 2013; 15:930-5. PubMed
  • Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT, Mitchell DA, Fecci PE, Sampson JH, Dranoff G. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. 2013; 12:597-615. PubMed
  • Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs 2013. PubMed
  • Alexander BM, Ligon KL, Wen PY. Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther 2013; 13:569-81. PubMed
  • Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S, Wen PY, Pollack IF, Zurakowski D, Kun LE, Prados MD, Rutkowski S, Kieran MW. Challenges With Defining Response to Antitumor Agents in Pediatric Neuro-Oncology: A Report From the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group. Pediatr Blood Cancer 2013. PubMed
  • Lee EQ, Nayak L, Wen PY, Reardon DA. Treatment Options in Newly Diagnosed Glioblastoma. Curr Treat Options Neurol 2013. PubMed
  • Alexander BM, Lee EQ, Reardon DA, Wen PY. Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother 2013; 13:369-87. PubMed
  • Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res 2013; 19:1567-76. PubMed
  • Villano JL, Wen PY, Lee EQ, Nayak L, Reardon DA, Rosenfeld MR. PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? : A point/counterpoint discussion. J. Neurooncol. 2013. PubMed
  • Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Reply to B. Freidlin et al. J Clin Oncol 2013; 31:970-1. PubMed
  • Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors. J Neurosurg 2013. PubMed
  • Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res 2013; 19:900-8. PubMed
  • Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F. A phase II trial of oral gimatecan for recurrent glioblastoma. J. Neurooncol. 2013; 111:347-53. PubMed
  • Shonka N, Piao Y, Gilbert M, Yung A, Chang S, Deangelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol 2013. PubMed
  • Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A, . Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma 2012; 54:58-61. PubMed
  • Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. 2012; 14:1511-8. PubMed
  • Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res 2012; 18:6032-6039. PubMed
  • Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J. Neurooncol. 2012; 110:89-98. PubMed
  • Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 2012; 30:3258-63. PubMed
  • Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012; 30:2307-13. PubMed
  • Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Initial treatment patterns over time for anaplastic oligodendroglial tumors. 2012; 14:761-7. PubMed
  • Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS ONE 2012; 7:e38881. PubMed
  • Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. 2011; 13:437-46. PubMed
  • Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, Deangelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central nervous system cancers. J Natl Compr Canc Netw 2011; 9:352-400. PubMed
  • Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Alfred Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. 2011. PubMed
  • Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. 2011; 13:353-61. PubMed
  • Mellinghoff IK, Lassman AB, Wen PY. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia 2011. PubMed
  • Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep 2011; 13:50-6. PubMed
  • Chaponis D, Barnes JW, Dellagatta JL, Kesari S, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J. Neurooncol. 2011. PubMed
  • Mou X, Kesari S, Wen PY, Huang X. Crude drugs as anticancer agents. Int J Clin Exp Med 2011; 4:17-25. PubMed
  • di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 2011; 71:19-28. PubMed
  • Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. 2011; 13:143-51. PubMed
  • Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S. Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J. Neurooncol. 2010. PubMed
  • Passarin MG, Wen PY, Vattemi E, Buffone E, Ghimenton C, Bontempini L, Ottaviani S, Musso AM, Pedersini R. Intravascular lymphomatosis and intracerebral haemorrhage. 2010; 31:793-7. PubMed
  • Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, Deangelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF, . A Phase I Trial of Tipifarnib with Radiation Therapy, with and without temozolomide, for Patients with Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J. Neurooncol. 2010. PubMed
  • Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J. Neurooncol. 2010; 99:365-78. PubMed
  • Wen PY. American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther 2010; 10:1367-9. PubMed
  • Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I Study of Vandetanib with Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 2010; 78:85-90. PubMed
  • Quant EC, Wen PY. Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials. Neuroimaging Clin N Am 2010; 20:425-48. PubMed
  • Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma. Curr Treat Options Neurol 2010; 12:321-33. PubMed
  • Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J. Neurooncol. 2010. PubMed
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817-23. PubMed
  • Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. 2010; 12:603-7. PubMed
  • Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. 2010; 12:466-72. PubMed
  • Wen PY. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? J Clin Oncol 2010; 28:1977-9. PubMed
  • Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010; 28:1963-72. PubMed
  • Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, Golby AJ, Wells WM, Warfield SK, Kikinis R, Bromfield EB. Morphological characteristics of brain tumors causing seizures. Arch Neurol 2010; 67:336-42. PubMed
  • Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Alfred Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Reply to W. Wick et al. J Clin Oncol 2010. PubMed
  • Wen PY, Norden AD, Drappatz J, Quant E. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 2010; 12:68-75. PubMed
  • Wen PY. Cerebral spinal fluid abnormalities in patients with paraneoplastic syndromes of the nervous system. J Neurol Neurosurg Psychiatry 2009; 81:3. PubMed
  • Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 2010; 15:1329-34. PubMed
  • Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J. Neurooncol. 2010; 96:211-7. PubMed
  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, . A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. 2010; 12:95-103. PubMed
  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, . A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. 2010; 12:87-94. PubMed
  • Wen PY, Brandes AA. Treatment of recurrent high-grade gliomas. Curr Opin Neurol 2010; 22:657-64. PubMed
  • Wen PY,Yung WK,Lamborn KR,Norden AD,Cloughesy TF,Abrey LE,Fine HA,Chang SM,Robins HI,Fink K,Deangelis LM,Mehta M,Di Tomaso E,Drappatz J,Kesari S,Ligon KL,Aldape K,Jain RK,Stiles CD,Egorin MJ,Prados MD. Phase II study of imatinib mesylate (Gleevec(R)) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro-oncol 2009; 11:853-60. PubMed
  • Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5:610-20. PubMed
  • Saad AG, Alyea EP, Wen PY, Degirolami U, Kesari S. Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation. J Clin Oncol 2009; 27:e147-9. PubMed
  • Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 2009; 15:6430-7. PubMed
  • Quant EC,Norden AD,Drappatz J,Muzikansky A,Doherty L,Lafrankie D,Ciampa A,Kesari S,Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-oncol 2009; 11:550-5. PubMed
  • Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-40. PubMed
  • Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009; 6:596-603. PubMed
  • Gerstner ER,McNamara MB,Norden AD,Lafrankie D,Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 2009; 94:97-101. PubMed
  • Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27:3518-25. PubMed
  • Samuel DP, Wen PY, Kieran MW. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs 2009; 18:973-83. PubMed
  • Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. 2009; 6:513-26. PubMed
  • Sorensen AG,Batchelor TT,Zhang WT,Chen PJ,Yeo P,Wang M,Jennings D,Wen PY,Lahdenranta J,Ancukiewicz M,di Tomaso E,Duda DG,Jain RK. A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Res 2009; 69:5296-300. PubMed
  • van den Bent MJ,Vogelbaum MA,Wen PY,Macdonald DR,Chang SM. End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria. J Clin Oncol 2009; 27:2905-8. PubMed
  • Norden AD,Drappatz J,Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep 2009; 9:231-40. PubMed
  • Drappatz J,Norden AD,Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 2009; 9:519-34. PubMed
  • Norden AD,Drappatz J,Muzikansky A,David K,Gerard M,McNamara MB,Phan P,Ross A,Kesari S,Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2008; 92:149-55. PubMed
  • Sauvageot CM,Weatherbee JL,Kesari S,Winters SE,Barnes J,Dellagatta J,Ramakrishna NR,Stiles CD,Kung AL,Kieran MW,Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro-oncol 2008; 11:109-21. PubMed
  • Richardson PG,Sonneveld P,Schuster MW,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Blade J,Boccadoro M,Cavenagh JD,Boral AL,Esseltine DL,Wen PY,Amato AA,Anderson KC,San Miguel J. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. British Journal of Haematology 2009; 144:895-903. PubMed
  • Norden AD,Drappatz J,Ciampa AS,Doherty L,LaFrankie DC,Kesari S,Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro-oncol 2008; 11:92-5. PubMed
  • Drappatz J,Wong ET,Schiff D,Kesari S,Batchelor TT,Doherty L,Lafrankie DC,Ramakrishna N,Weiss S,Smith ST,Ciampa A,Zimmerman J,Ostrowsky L,David K,Norden A,Barron L,Sceppa C,Black PM,Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2008; 73:222-7. PubMed
  • Kesari S,Schiff D,Drappatz J,LaFrankie D,Doherty L,Macklin EA,Muzikansky A,Santagata S,Ligon KL,Norden AD,Ciampa A,Bradshaw J,Levy B,Radakovic G,Ramakrishna N,Black PM,Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 2009; 15:330-7. PubMed
  • Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2009; 2:ra82. PubMed
  • Wen PY. New developments in targeted molecular therapies for glioblastoma. Expert Rev Anticancer Ther 2008; 9:7-10. PubMed
  • Norden AD,Drappatz J,Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008; 7:1152-60. PubMed
  • Dietrich J,Norden AD,Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol 2008; 21:736-44. PubMed
  • Sorensen AG,Batchelor TT,Wen PY,Zhang WT,Jain RK. Response criteria for glioma. Nat Clin Pract Oncol 2008; 5:634-44. PubMed
  • Norden AD,Drappatz J,Wen PY. Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 2008; 20:652-61. PubMed
  • Bracht LK,Wen P,Meyerhardt JA,Kulke MH,Hornick JL,Redston M,LaFrankie DC,Black PM,Kesari S,Norden A,Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol 2008; 26:4843-4. PubMed
  • Haining WN,Davies J,Kanzler H,Drury L,Brenn T,Evans J,Angelosanto J,Rivoli S,Russell K,George S,Sims P,Neuberg D,Li X,Kutok J,Morgan J,Wen P,Demetri G,Coffman RL,Nadler LM. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 2008; 14:5626-34. PubMed
  • Fadul CE,Wen PY,Kim L,Olson JJ. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol 2008; 89:339-57. PubMed
  • Chang SM,Lamborn KR,Kuhn JG,Yung WK,Gilbert MR,Wen PY,Fine HA,Mehta MP,DeAngelis LM,Lieberman FS,Cloughesy TF,Robins HI,Abrey LE,Prados MD. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro-oncol 2008; 10:631-42. PubMed
  • Wen PY,Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507. PubMed
  • Kesari S,Drappatz J,Akar S,Vergilio JA,Wen PY,Soiffer RJ,Stone RM,Deangelo DJ. Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol 2008; 26:3279-81. PubMed
  • Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-oncol 2008; 10:300-8. PubMed
  • Kesari S, Kim RS, Markos V, Drappatz J, Wen PY, Pruitt AA. Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. J Neurooncol 2008; 88:175-83. PubMed
  • Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 2007; 61:1059-67. PubMed
  • Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008; 8:541-53. PubMed
  • Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncol 2008; 10:162-70. PubMed
  • Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70:779-87. PubMed
  • Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2007; 86:211-5. PubMed
  • Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 2007; 13:7401-6. PubMed
  • Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res 2007; 13:7133-8. PubMed
  • Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin 2007; 25:1035-71, ix. PubMed
  • Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 2007; 7:1537-60. PubMed
  • Cavaliere R, Wen PY, Schiff D. Novel therapies for malignant gliomas. Neurol Clin 2007; 25:1141-71, x. PubMed
  • Monje ML, Ramakrishna NR, Young G, Drappatz J, Doherty LM, Wen PY, Kesari S. Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. J Neurooncol 2007; 84:179-83. PubMed
  • Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-oncol 2007; 9:354-63. PubMed
  • Wen PY, DeAngelis LM. Chemotherapy for low-grade gliomas: emerging consensus on its benefits. Neurology 2007; 68:1762-3. PubMed
  • Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov Y, Zenklusen JC, Fine HA, Maric D, Wen PY, De Girolami U, Black PM, Wu WW, Shen RF, Jeffries NO, Kang DW, Park JK. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. Journal of the National Cancer Institute 2007; 99:639-52. PubMed
  • Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets 2007; 11:473-96. PubMed
  • Chheda MG, Drappatz J, Greenberger NJ, Kesari S, Weiss SE, Gigas DC, Doherty LM, Wen PY. Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology 2007; 68:955-6. PubMed
  • Narin O, Drappatz J, Doherty LM, Wen PY, Kesari S. Cerebrospinal fluid spread of anaplastic glioma. J Clin Oncol 2007; 25:596-7. PubMed
  • Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2006; 81:271-7. PubMed
  • Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95. PubMed
  • Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J Neurooncol 2006; 80:313-32. PubMed
  • Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, Richardson A, Khatry D, Feng B, Sinha R, Louis DN, Quackenbush J, Black PM, Chin L, DePinho RA. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 2006; 66:11502-13. PubMed
  • Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006; 12:279-92. PubMed
  • Drappatz J, Wen PY. Chemotherapy and targeted molecular therapies for brain metastases. Expert Rev Neurother 2006; 6:1465-79. PubMed
  • Wen PY, Drappatz J. Novel therapies for meningiomas. Expert Rev Neurother 2006; 6:1447-64. PubMed
  • Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, J. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006; 24:4517-20. PubMed
  • Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-907. PubMed
  • Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006; 24:3651-6. PubMed
  • Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen PY. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006; 67:156-8. PubMed
  • Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113-20. PubMed
  • Wen PY, Kesari S, Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther 2006; 6:733-54. PubMed
  • Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J,. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 2006; 8:189-93. PubMed
  • Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006; 11:152-64. PubMed
  • Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-oncol 2006; 8:38-46. PubMed
  • Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 2006; 8:58-70. PubMed
  • Norden AD, Wen PY, Kesari S. Brain metastases. Curr Opin Neurol 2005; 18:654-61. PubMed
  • Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Neurol Neurosci Rep 2005; 5:186-97. PubMed
  • Wen PY, Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep 2004; 4:218-27. PubMed
  • Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J,. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 2004; 6:44-54. PubMed
  • Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 21:2299-304. PubMed
  • Wen PY, Schiff D. Neurologic complications of solid tumors. Neurol Clin 2003; 21:107-40, viii. PubMed
  • Wen PY, Glantz MJ. Neurologic complications of cancer. Preface. Neurol Clin 2003; 21:xi-xiii. PubMed
  • Plotkin SR, Wen PY. Neurologic complications of cancer therapy. Neurol Clin 2003; 21:279-318, x. PubMed
  • Jeter MD, J. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53:394-400. PubMed
  • Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002; 14:299-307. PubMed
  • Schiff D, O'Neill B, Wijdicks E, Antin JH, Wen PY. Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation? Neurology 2001; 57:1486-8. PubMed
  • Wen PY, Loeffler JS. Brain metastases. Curr Treat Options Oncol 2002; 1:447-58. PubMed
  • Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:1886-93. PubMed
  • Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-15. PubMed
  • Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60:166-93. PubMed
  • Wen PY, Loeffler JS. Management of brain metastases. Oncology (Huntingt) 1999; 13:941-54, 957-61; discussio. PubMed
  • Mamon HJ, Wen PY, Burns AC, Loeffler JS. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 1999; 40:341-4. PubMed
  • Shrieve DC, Alexander E, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999; 90:72-7. PubMed
  • Talcott JA, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, Lu C, Jolesz F. Assessing suspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodes. Support Care Cancer 1999; 7:31-8. PubMed
  • Lu C, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, Collins CA, Jolesz F, Talcott JA. Suspected spinal cord compression in breast cancer patients: a multidisciplinary risk assessment. Breast Cancer Res Treat 1999; 51:121-31. PubMed
  • Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KZ, Cook CU, Sahu SK, Black PM, Adelstein SJ. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med 1998; 39:1148-54. PubMed
  • Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 1998; 9:1409-17. PubMed
  • Schiff D, Batchelor T, Wen PY. Neurologic emergencies in cancer patients. Neurol Clin 1998; 16:449-83. PubMed
  • Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA. Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol 1998; 4:194-203. PubMed
  • Hakim R, Alexander E, Loeffler JS, Shrieve DC, Wen P, Fallon MP, Stieg PE, Black PM. Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery 1998; 42:446-53; discussion 453-4. PubMed
  • Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E, Black PM, Coleman CN. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys 1998; 40:65-70. PubMed
  • Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH. Guillain-Barrsyndrome following allogeneic bone marrow transplantation. Neurology 1997; 49:1711-4. PubMed
  • Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG, Fine HA. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997; 3:1145-9. PubMed
  • Wen PY, Feske SK, Teoh SK, Stieg PE. Cerebral hemorrhage in a patient taking fenfluramine and phentermine for obesity. Neurology 1997; 49:632-3. PubMed
  • Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997; 3:437-42. PubMed
  • Fine HA, Wen PY, Robertson M, O'Neill A, Kowal J, Loeffler JS, Black PM. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res 1998; 3:381-7. PubMed
  • Sahu SK, Wen PY, Foulon CF, Nagel JS, Black PM, Adelstein SJ, Kassis AI. Intrathecal 5-[125I]iodo-2'-deoxyuridine in a rat model of leptomeningeal metastases. J Nucl Med 1997; 38:386-90. PubMed
  • Lynch TJ, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol 1997; 15:723-34. PubMed
  • Packard AB, Barbarics E, Kronauge JF, Wen PY, Day PJ, Jones AG. Comparison of uptake of 99mTc-alkylisonitriles in the rat 9L gliosarcoma tumor model. Nucl Med Biol 1997; 24:21-5. PubMed
  • Manome Y, Wen PY, Chen L, Tanaka T, Dong Y, Yamazoe M, Hirshowitz A, Kufe DW, Fine HA. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther 1996; 3:513-20. PubMed
  • Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 1996; 2:567-73. PubMed
  • Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirschowitz EA, Crystal R, Weichselbaum R, Kufe DW, Fine HA. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996; 7:713-20. PubMed
  • Kassis AI, Tumeh SS, Wen PY, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Bailey NO, Castronovo FP, Mariani G, Black PM, Adelstein SJ. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med 1996; 37:19S-22S. PubMed
  • Gaa J, Warach S, Wen P, Thangaraj V, Wielopolski P, Edelman RR. Noninvasive perfusion imaging of human brain tumors with EPISTAR. Eur Radiol 1996; 6:518-22. PubMed
  • Schiff D, Wen PY. Uncommon brain tumors. Neurol Clin 1995; 13:953-74. PubMed
  • Wen PY, Fine HA, Black PM, Shrieve DC, Alexander E, Loeffler JS. High-grade astrocytomas. Neurol Clin 1995; 13:875-900. PubMed
  • Manome Y, Wen PY, Hershowitz A, Tanaka T, Rollins BJ, Kufe DW, Fine HA. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother 1995; 41:227-35. PubMed
  • Geller EB, Wen PY. Migraine with aura as the presentation of leukemia. Headache 1995; 35:560-2. PubMed
  • Loeffler JS, Shrieve DC, Wen PY, Fine HA, Kooy HM, Addesa AE, Black PM, Alexander E. Radiosurgery for Intracranial Malignancies. Semin Radiat Oncol 2000; 5:225-234. PubMed
  • Shrieve DC, Alexander E, Wen PY, Fine HA, Kooy HM, Black PM, Loeffler JS. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995; 36:275-82; discussion 282-4. PubMed
  • Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995; 87:34-40. PubMed
  • Wen PY, Loeffler JS. Advances in the diagnosis and management of pituitary tumors. Curr Opin Oncol 1995; 7:56-62. PubMed
  • Hersh B, Dalmau J, Dangond F, Gultekin S, Geller E, Wen PY. Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology 1994; 44:1754-5. PubMed
  • Riese NE, Loeffler JS, Wen P, Alexander E, Black PM, Coleman CN. A phase I study of etanidazole and radiotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 1994; 29:617-20. PubMed
  • Wen PY, Alexander E, Black PM, Fine HA, Riese N, Levin JM, Coleman CN, Loeffler JS. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 1994; 73:3029-36. PubMed
  • Wen PY, Alexander E, Loeffler JS. Stereotactic radiosurgery treats intracranial lesions. Diagn Imaging (San Franc) 1994; 16:76-80, 107. PubMed
  • Wen P, Shanti I. Use of cerebral imaging in patients with headaches. Arch Intern Med 1993; 153:1613-4. PubMed
  • Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43:1111-4. PubMed
  • Schiff D, Feske SK, Wen PY. Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med 1993; 153:389-90. PubMed
  • Slivka A, Wen PY, Shea WM, Loeffler JS. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 1993; 94:216-9. PubMed
  • Loeffler JS, Alexander E, Shea WM, Wen PY, Fine HA, Kooy HM, Black PM. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992; 10:1379-85. PubMed
  • Wen P. Major histocompatibility antigens in murine tumors. J Neurosurg 1992; 76:1048-50. PubMed
  • Wen PY, Blanchard KL, Block CC, Loeffler JS, Davis DG, Lacroix LA, Antin JH. Development of Lhermitte's sign after bone marrow transplantation. Cancer 1992; 69:2262-6. PubMed
  • Sandson TA, Wen PY, LeMay M. Reversed cerebral asymmetry in women with breast cancer. Lancet 1992; 339:523-4. PubMed
  • Lampson LA, Wen P, Roman VA, Morris JH, Sarid JA. Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res 1992; 52:1018-25. PubMed
  • Wen PY, Lampson MA, Lampson LA. Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J Neuroimmunol 1992; 36:57-68. PubMed
  • Coleman CN, Noll L, Riese N, Buswell L, Howes AE, Loeffler JS, Alexander E, Wen P, Harris JR, Kramer RA. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys 1992; 22:577-80. PubMed
  • Dangond F, Lacomis D, Schwartz RB, Wen PY, Samuels MA. Acute disseminated encephalomyelitis progressing to hemorrhagic encephalitis. Neurology 1991; 41:1697-8. PubMed
  • Loeffler JS, Alexander E, Wen PY, Shea WM, Coleman CN, Kooy HM, Fine HA, Nedzi LA, Silver B, Riese NE. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 1990; 82:1918-21. PubMed
  • Loeffler JS, Alexander E, Hochberg FH, Wen PY, Morris JH, Schoene WC, Siddon RL, Morse RH, Black PM. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 1990; 19:1455-62. PubMed
  • Kassis AI, Van den Abbeele AD, Wen PY, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ. Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res 1990; 50:5199-203. PubMed
  • Wen P, Loeffler JS, Morris JH, Lampson LA. The effects of irradiation on major histocompatibility complex expression and lymphocytic infiltration in the normal rat brain and the 9L gliosarcoma brain tumor model. J Neuroimmunol 1990; 27:239-44. PubMed
  • Loeffler JS, Siddon RL, Wen PY, Nedzi LA, Alexander E. Stereotactic radiosurgery of the brain using a standard linear accelerator: a study of early and late effects. Radiother Oncol 1990; 17:311-21. PubMed
  • Loeffler JS, Kooy HM, Wen PY, Fine HA, Cheng CW, Mannarino EG, Tsai JS, Alexander E. The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol 1990; 8:576-82. PubMed
Hide